




Single-cell Biomarker Discovery

Scailyte is an award-winning startup & ETH Zürich spin-off developing and utilizing an AI-based platform for biomarker discovery from single-cell and clinical data.



On a mission to save millions of lives.

Single-cell data offers unprecedented biological resolution but is overly complex to analyze and interpret. With our data analytics platform ScaiVision®, we unlock the full potential of single-cell data and extract clinically relevant insights. We partner with leading clinicians to generate high-quality, single-cell data sets and deliver ultra-sensitive biomarkers that will improve patient outcomes.

Highlights

Finalist for Nature Spinoff Prize

Scailyte is among the 12 finalists in a global competition for innovative University spin-offs organized by [Nature Research and Merck](#).

Closed round CHF 3.7M

On August 12th, Scailyte closed the pre-series A financing round of total CHF 3.74M led by Swisscom Ventures, joined by 4FO ventures, Hemex, investiere and private investors.

Swissnex San Francisco

In October Scailyte participates in the [Swissnex San Francisco Market Validation camp](#), to gain exposure to industry- and clinical partners and secure a cooperation for co-discovery/co-development with a US partner.

ScaiVision® advancements

Scailyte has discovered a biomarker for predicting critical outcome in Covid19 and pneumonia patients (patent pending). Validation is planned for Q4-2020.

The functionality of ScaiVision has been extended to allow integration of single-cell and multi-parametric clinical data (in Covid19/ARDS).

Outlook

On the way to become a leader in biomarker discovery through single-cell technology, Scailyte continues to expand the clinical network and the access to single-cell data.

Scailyte is implementing a Quality and Information Management System in compliance with ISO 13485 and ISO 27001.

Scailyte kicked-off the preparation for the Series A financing round (8-10M) starting Q4 of 2020.




www.scailyte.com
[Dr. Peter Nestorov](#)
CEO





Single-cell Biomarker Discovery

Scailyte is an award-winning startup & ETH Zürich spin-off developing and utilizing an AI-based platform for biomarker discovery from single-cell and clinical data.



investiere venture capital

Invest in Cutting -Edge Innovation



Susanne Schorsch
Investment Manager at investiere

"Scailyte® has developed the first commercial discovery engine that applies artificial intelligence to single-cell data in order to identify cellular biomarkers. We are excited to support the Scailyte team on its quest to enable precision diagnostics", says Susanne Schorsch, Investment Manager at investiere. "Scailyte is working on pipeline candidates for indications like CTCL and endometriosis that affect millions of patients, and doctors are in desperate need of an early-stage diagnostic that does not exist today."

Collaboration Karolinska Institutet Sweden

"I am happy to join forces with Scailyte AG to use single-cell analyses and advanced analytics towards better understanding human immune-mediated diseases"



Petter Brodin
Associate Professor of Immunology, Karolinska Institutet



www.scailyte.com
Dr. Peter Nestorov
CEO

